No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
EDIT Editas Medicine
- 5.320
- -0.240-4.32%
Close May 10 16:00 ET
- 5.348
- +0.028+0.53%
Post 19:41 ET
437.51MMarket Cap-2570P/E (TTM)
5.690High5.250Low1.64MVolume5.520Open5.560Pre Close8.79MTurnover2.14%Turnover RatioLossP/E (Static)82.24MShares11.91052wk High1.49P/B407.19MFloat Cap4.91052wk Low--Dividend TTM76.54MShs Float99.950Historical High--Div YieldTTM7.91%Amplitude4.910Historical Low5.369Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Editas Medicine Preclinical Data Highlights Advancement of in Vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications Data to support development of the Company's in vivo gene editing medicines pipeline
Buy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth Potential
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript
Express News | Citigroup Maintains Buy on Editas Medicine, Lowers Price Target to $15
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
Clinical-stage biotech Editas Medicine (NASDAQ: EDIT) delivered quarterly results that fell well short of expectations on Wednesday.
Editas Medicine Price Target Announced at $7.00/Share by Morgan Stanley
Editas Medicine Price Target Announced at $7.00/Share by Morgan Stanley
Comments
$Editas Medicine(EDIT.US$
NEWS
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine demonstrated significant scientific advances in in vivo gene editing technologies, including lipid nanoparticle formulations for efficient delivery and guide RNA modifications to enhance editing potency.
The efficacy of AsCas12a nuclease in vivo was demonstrated by Editas Medicine, sho...
NEWS
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine demonstrated significant scientific advances in in vivo gene editing technologies, including lipid nanoparticle formulations for efficient delivery and guide RNA modifications to enhance editing potency.
The efficacy of AsCas12a nuclease in vivo was demonstrated by Editas Medicine, sho...
1
$Editas Medicine(EDIT.US$
NEWS
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
NEWS
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
1
Despite Editas Medicine's stock price surge, its P/S ratio remains modest due to inferior revenue forecasts. Without revenue improvement, the P/S ratio will continue to limit the share price.
Analysts are divided on Editas Medicine's performance, with some optimistic and others pessimistic. The projected increase in losses next year is worrisome, despite the rise in revenue estimates. The company's revenue growth is anticipated to lag behind the broader industry, posing a potential downside.
Increased forecast losses for Editas Medicine indicate potential issues, with revenues expected to grow slower than the market. The drastic downgrade to this year's forecasts raises caution towards the company's future performance.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
